Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Global Fund-Financed Programs Reaching More People, Report Shows
The most recent statistics on programs funded in 140 countries through the Global Fund to Fight AIDS, Tuberculosis and Malaria released Wednesday reveal "[m]ore than 2 million people living with HIV have been reached with life-saving treatment," the UN News Centre reports (7/8).

Pfizer's Oral JAK-3 Inhibitor Demonstrates Statistically Significant Response For Patients With Rheumatoid Arthritis, New Phase 2 Studies Show
Pfizer announced today that data from two new mid-stage clinical studies of the company"s oral JAK-3 inhibitor, CP-690,550, showed statistically significant response versus placebo for patients with rheumatoid arthritis (RA). Data from these two Phase 2 trials and one ongoing open-label safety study are being presented this week at the 10th Annual Congress of the European League Against Rheumatism (EULAR). These results confirm findings from two previously reported Phase 2 studies in RA and have been used to support dose selection for Phase 3.
News of the day
Scientists Test New Drug Combo Against Breast Cancer
The American Cancer Society estimates 192,000 new cases of breast cancer will be diagnosed in the United States this year with more than 40,000 individuals dying from the disease. In New Jersey alone 6,400 new cases are expected with 1,400 deaths. In an effort to combat such statistics, researchers at The Cancer Institute of New Jersey (CINJ) have opened a clinical trial, which will evaluate a new drug combination for patients with breast cancer who are set to undergo surgery to remove the tumor. At focus is the process of stopping angiogenesis (blood vessel growth), which is necessary for cancer tumors to grow and spread. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.
Medical Devices

Intravenous COTI-2 In Combination With Doxil(R) Is More Effective Than Treatment With Doxil Alone In An Animal Model Of Human Ovarian Cancer

Critical Outcome Technologies Inc. (TSX VENTURE:COT), announced positive results today from combination agent animal experiments carried out at a prominent American cancer research facility. The results provide strong supportive evidence for the continued evaluation of COTI-2 in combination with conventional single agent therapy for the treatment of ovarian cancer: - Tumor growth inhibition was significantly greater in the COTI-2 plus Doxil treated animals compared to the Doxil control group treated animals with: -- 12.5 mg/kg COTI-2 + 2 mg/kg Doxil causing 57% tumor growth inhibition -- 25 mg/kg COTI-2 + 2 mg/kg Doxil causing 54% tumor growth inhibition -- 2mg/kg Doxil control causing 29% tumor growth inhibition - The effectiveness of the combination treatments with COTI-2 was apparent early in the study (day 4) and increased throughout the remainder of the study. - Combination treatments were well tolerated. "We are delighted to see that intravenous COTI-2 in combination with Doxil showed superior treatment results compared to Doxil alone as measured by significant tumor growth inhibition in an animal model of an aggressive human ovarian cancer (A2780). These results are significant because they add to the impressive data set of COTI-2, showing effectiveness, particularly in combination with first and second line agents, against multiple cancers and low toxicity," said Dr. Wayne Danter, President and Chief Scientific Officer of Critical Outcome Technologies Inc. (COTI). "COTI will share this new data with parties who have expressed interest in a commercial partnership related to COTI-2," said Mr. Michael Cloutier, Chief Executive Officer of COTI. The Company intends to repeat this study using an oral formulation of COTI-2 to compare the effectiveness of oral COTI-2 in an animal model of human disease. The Company is also advising of a correction to its June 10, 2009 press release, which announced a brokered private placement as this should have read a non-brokered private placement. Critical Outcome Technologies Inc. (COTI)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009